Skip to main content

Advertisement

SpringerLink
Log in

The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA+-M2BP) was developed recently as a predictive marker of progression to liver fibrosis and hepatocellular carcinoma (HCC) in patients seropositive for hepatitis C virus (HCV). We retrospectively analyzed 16 HCV-seropositive patients who received systemic chemotherapy for hematologic malignancies to evaluate the usefulness of WFA+-M2BP for predicting HCV-related complications. These were defined as the onset of significant liver damage (LD) with increased HCV RNA levels, leading to interrupted or discontinued chemotherapy or the occurrence of HCC after chemotherapy. Baseline WFA+-M2BP levels were determined using preserved serum samples. The median level of WFA+-M2BP was 1.59 [cutoff index (C.O.I.) value range 0.38–6.66]. With a median follow-up of 623 days (range 120–2404), LD and HCC were observed in three and two patients, respectively. Detectable HCV RNA and WFA+-M2BP ≥2.0 C.O.I. at baseline were identified as risk factors for these HCV-related complications (P = 0.034 and P = 0.005, respectively). The sensitivity, specificity, and positive and negative predictive values of the WFA+-M2BP level (cutoff point: 2.0 C.O.I.) for the occurrence of HCV-related complications were 100.0, 81.8, 71.4, and 100.0 %, respectively. WFA+-M2BP may be a useful marker for the prediction of HCV-related complications in HCV-seropositive patients following systemic chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

WFA+-M2BP:

Wisteria floribunda agglutinin-positive human Mac-2-binding protein

HCC:

Hepatocellular carcinoma

HCV:

Hepatitis C virus

HBV:

Hepatitis B virus

LD:

Liver damage

LC:

Liver cirrhosis

C.O.I.:

Cutoff index

ALT:

Alanine transaminase

LF:

Liver failure

PT:

Prothrombin time

ROC:

Receiver operating characteristic

IFN:

Interferon

DAA:

Direct-acting antiviral

References

  1. Lauer GM, Walker BD. Hepatitis C virus infection. New England J Med. 2001;345:41–52.

    Article  CAS  Google Scholar 

  2. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. New England J Med. 1995;332:1463–6.

  3. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D’Errico A, Simon N, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345:413–5.

    Article  PubMed  Google Scholar 

  4. Pioltelli P, Zehender G, Monti G, Monteverde A, Galli M. HCV and non-Hodgkin lymphoma. Lancet. 1996;347:624–5.

    Article  CAS  PubMed  Google Scholar 

  5. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125:1723–32.

    Article  PubMed  Google Scholar 

  6. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004;95:745–52.

    Article  CAS  PubMed  Google Scholar 

  7. Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol. 2005;74:158–65.

    Article  PubMed  Google Scholar 

  8. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol Off J American Soc Clin Oncol. 2005;23:468–73.

    Article  CAS  Google Scholar 

  9. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol Off J American Soc Clin Oncol. 2006;24:953–60.

    Article  Google Scholar 

  10. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol Off J Euro Soc Med Oncol/ESMO. 2006;17:1434–40.

    Article  CAS  Google Scholar 

  11. Arcaini L, Merli M, Passamonti F, Bruno R, Brusamolino E, Sacchi P, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol. 2010;85:46–50.

    PubMed  Google Scholar 

  12. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116:5119–25.

    Article  CAS  PubMed  Google Scholar 

  13. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nature Rev Clin Oncol. 2012;9:156–66.

    Article  CAS  Google Scholar 

  14. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.

    Article  PubMed  Google Scholar 

  15. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res Off J Japan Soc Hepatol. 2013;43:113–21.

    Article  Google Scholar 

  16. Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99:489–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015;50:76–84.

    Article  CAS  PubMed  Google Scholar 

  19. Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2015;50:776–84.

    Article  CAS  PubMed  Google Scholar 

  20. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology. 2014;60:1563–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sasaki R, Yamasaki K, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis c after sustained virological response. PLoS ONE. 2015;10:e0129053.

    Article  PubMed  Google Scholar 

  22. Tamaki N, Kurosaki M, Kuno A, Korenaga M, Togayachi A, Gotoh M, et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res Off J Japan Soc Hepatol. 2015;45:E82–8.

    Article  CAS  Google Scholar 

  23. Fujiyoshi M, Kuno A, Gotoh M, Fukai M, Yokoo H, Kamachi H, et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol. 2015;50:1134–44.

    Article  CAS  PubMed  Google Scholar 

  24. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr. 2007;96:644–7.

    Article  PubMed  Google Scholar 

  25. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. New England J Med. 2012;366:216–24.

    Article  CAS  Google Scholar 

  26. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England J Med. 2013;368:34–44.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Ms. Chiori Fukuyama and Dr. Shintaro Ogawa (Nagoya City University Graduate School of Medical Sciences, Nagoya) for storing and measuring the samples used in this study. This study was supported in part by the Research Program on Hepatitis from Japan Agency for Medical Research and development, AMED (Y.T.).

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan

    Haruhito Totani, Shigeru Kusumoto, Nana Suzuki, Shinya Hagiwara, Shiori Kinoshita, Asahi Ito, Masaki Ri, Takashi Ishida, Hirokazu Komatsu & Shinsuke Iida

  2. Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Yasuhito Tanaka & Etsuko Iio

Authors
  1. Haruhito Totani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigeru Kusumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhito Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nana Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinya Hagiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shiori Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Etsuko Iio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Asahi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masaki Ri
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hirokazu Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shinsuke Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeru Kusumoto.

Ethics declarations

Conflict of interest

Yasuhito Tanaka: Research funding and honoraria from Sysmex Corporation, Bristol-Myers Squibb Co., Chugai Pharmaceutical Co. Ltd. Masaki Ri: Research funding from Celgene K.K. Takashi Ishida: Research funding from Kyowa Hakko Kirin Co., Ltd., Bayer Pharma AG, and Celgene K.K., and honoraria from Kyowa Hakko Kirin Co., Ltd. Shinsuke Iida: Research funding from Bristol-Myers Squibb Co., Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Celgene K.K., Kyowa Hakko Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., and honoraria from Celgene K.K., Janssen pharmaceutical K.K. and Ono Pharmaceutical Co. Ltd.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Totani, H., Kusumoto, S., Tanaka, Y. et al. The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy. Int J Hematol 104, 384–391 (2016). https://doi.org/10.1007/s12185-016-2033-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-016-2033-z

Keywords

Search

Navigation